Form 4: Centessa Pharmaceuticals CEO Saurabh Saha Reports Changes in Beneficial Ownership
SEC Form 4 Filing
CEO Saurabh Saha reports the withholding of 36,263 ordinary shares by Centessa Pharmaceuticals to cover tax obligations related to vesting restricted share units, alongside holdings of 831,924 directly owned shares and 38,000 shares held in trust.
Summary
- On June 30, 2024, Centessa Pharmaceuticals withheld 36,263 ordinary shares from CEO Saurabh Saha to cover tax withholding obligations related to the vesting of restricted share units.
- The price per share for the tax withholding was $9.03.
- Following the transaction, Saha directly owns 831,924 ordinary shares.
- Saha also indirectly owns 38,000 ordinary shares through a trust where he and his spouse serve as trustees.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing detailing a standard tax withholding transaction. It doesn't inherently indicate positive or negative sentiment, but rather reflects normal corporate operations.
Industry Context
This is a standard SEC Form 4 filing, which is a routine part of corporate governance and transparency, ensuring that insider transactions are publicly disclosed.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the withholding of shares for tax purposes, which is a normal part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | Date of transaction where shares were withheld for tax obligations. |
| 07/02/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.